1
|
Li R, Liang H, Li J, Shao Z, Yang D, Bao J, Wang K, Xi W, Gao Z, Guo R, Mu X. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study. BMC Cancer 2024; 24:107. [PMID: 38238648 PMCID: PMC10797919 DOI: 10.1186/s12885-024-11860-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Accepted: 12/20/2023] [Indexed: 01/22/2024] Open
Abstract
BACKGROUND Paclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in patients with advanced NSCLC. METHODS In this multicenter, retrospective, real-world study, patients with advanced NSCLC who were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in three centers (Peking University People's Hospital as the lead center) in China between 2016 and 2022 were included. Progression-free survival (PFS), overall survival (OS), objective response rate, disease control rate, and adverse events (AEs) were evaluated. RESULTS A total of 49 patients were included, with 33 (67.3%) receiving paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line treatment. There were 34 patients (69.4%) diagnosed with squamous cell carcinoma and 15 (30.6%) with adenocarcinoma. The median follow-up was 20.5 (range: 3.1-41.1) months. The median PFS and OS of all patients were 9.7 months (95% confidence interval [CI], 7.0-12.4) and 30.5 months (95% CI, not evaluable-not evaluable), respectively. Patients with squamous cell carcinoma and adenocarcinoma had median PFS of 11 months (95%CI, 6.5-15.5) and 9.3 months (95%CI, 7.0-12.4), respectively. The median PFS was 9.9 months (95%CI, 7.1-12.7) in patients who received the combined regimen as first-line treatment. Treatment-related AEs of any grade were observed in 25 (51.0%) patients, and AEs of grade 3 or worse were observed in nine patients (18.4%). The most common treatment-related AEs were myelosuppression (14.3%) and fever (10.2%). CONCLUSIONS Paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor prolonged the PFS in advanced NSCLC with acceptable safety, which was worthy of clinical application.
Collapse
Affiliation(s)
- Ran Li
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Hongge Liang
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Jun Li
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China
| | - Zhenyu Shao
- Department of Radiation Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China
| | - Donghong Yang
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Jing Bao
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Keqiang Wang
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Wen Xi
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Zhancheng Gao
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China
| | - Renhua Guo
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China
| | - Xinlin Mu
- Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
| |
Collapse
|
2
|
Radhakrishnan D, Mohanan S, Choi G, Choy JH, Tiburcius S, Trinh HT, Bolan S, Verrills N, Tanwar P, Karakoti A, Vinu A. The emergence of nanoporous materials in lung cancer therapy. SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS 2022; 23:225-274. [PMID: 35875329 PMCID: PMC9307116 DOI: 10.1080/14686996.2022.2052181] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/31/2022] [Accepted: 03/08/2022] [Indexed: 06/15/2023]
Abstract
Lung cancer is one of the most common cancers, affecting more than 2.1 million people across the globe every year. A very high occurrence and mortality rate of lung cancer have prompted active research in this area with both conventional and novel forms of therapies including the use of nanomaterials based drug delivery agents. Specifically, the unique physico-chemical and biological properties of porous nanomaterials have gained significant momentum as drug delivery agents for delivering a combination of drugs or merging diagnosis with targeted therapy for cancer treatment. This review focuses on the emergence of nano-porous materials for drug delivery in lung cancer. The review analyses the currently used nanoporous materials, including inorganic, organic and hybrid porous materials for delivering drugs for various types of therapies, including chemo, radio and phototherapy. It also analyses the selected research on stimuli-responsive nanoporous materials for drug delivery in lung cancer before summarizing the various findings and projecting the future of emerging trends. This review provides a strong foundation for the current status of the research on nanoporous materials, their limitations and the potential for improving their design to overcome the unique challenges of delivering drugs for the treatment of lung cancer.
Collapse
Affiliation(s)
- Deepika Radhakrishnan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Shan Mohanan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Goeun Choi
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan31116, Republic of Korea
- College of Science and Technology, Dankook University, Cheonan31116, Republic of Korea
- Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan31116, Korea
| | - Jin-Ho Choy
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan31116, Republic of Korea
- Course, College of Medicine, Dankook UniversityDepartment of Pre-medical, Cheonan31116, Korea
- Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama226-8503, Japan
| | - Steffi Tiburcius
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Hoang Trung Trinh
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Shankar Bolan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Nikki Verrills
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellness, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Pradeep Tanwar
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellness, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Ajay Karakoti
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Ajayan Vinu
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| |
Collapse
|
3
|
Canão F, Ferreira H, Neves NM. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review. J Cancer Res Clin Oncol 2022; 148:2375-2386. [PMID: 35660950 DOI: 10.1007/s00432-022-04079-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 05/19/2022] [Indexed: 12/17/2022]
Abstract
PURPOSE Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efficacy of liposomal formulations in lung cancer treatment. METHODS Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the effects of liposomal formulations in lung cancer patients were considered eligible. RESULTS Twenty two selected studies present different treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verified that combination of liposomal cisplatin and paclitaxel led to a statistically significant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could benefit from this formulation were also provided. CONCLUSION This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patients' cohort considering more responsive subgroups would be beneficial to strengthen the scientific and clinical evidence of the results herein reported.
Collapse
Affiliation(s)
- Filipa Canão
- School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal
| | - Helena Ferreira
- 3B's Research Group, I3Bs Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, 4805-017, Barco/Guimarães, Portugal.
- ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
| | - Nuno M Neves
- 3B's Research Group, I3Bs Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, 4805-017, Barco/Guimarães, Portugal.
- ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
| |
Collapse
|